Navigation Links
NORD and DIA to Host Conference on Rare Diseases and Orphan Products
Date:9/14/2011

WASHINGTON, Sept. 14, 2011 /PRNewswire-USNewswire/ -- The National Organization for Rare Disorders (NORD) and the Drug Information Association (DIA) will host the U.S. Conference on Rare Diseases and Orphan Products in Washington, D.C. October 11-13.  Everyone with an interest in rare diseases or orphan products is invited.

(Logo: http://photos.prnewswire.com/prnh/20110719/DC37656LOGO-b)

"This conference will be truly unique in that it will draw together all the stakeholders from government, industry, academia and patient organizations," said Peter L. Saltonstall, president and CEO of NORD.  "Most of the nearly 7,000 rare diseases don't have FDA-approved treatments.  The purpose of this conference is to bring everyone together—government, industry, medical researchers, investors and patients—to examine the challenges and opportunities."

NORD is a nonprofit organization representing all Americans affected by rare diseases.  DIA is a nonprofit, global professional association of members involved in pharmaceutical and medical device discovery, development, and management.

Senior staff from the National Institutes of Health (NIH) and Food and Drug Administration (FDA) will speak at the conference, along with thought leaders from the pharmaceutical industry, medical researchers, and the investment community.  Speakers will include:

  • NIH Director Francis Collins, MD, PhD
  • Social Security Commissioner Michael Astrue
  • Christopher P. Austin, MD, PhD, Scientific Director, NIH Center for Translational Therapeutics
  • Janet Woodcock, MD, Director of FDA's Center for Drug Evaluation and Research
  • John K. Jenkins, MD, Director, Office of New Drugs, FDA Center for Drug Evaluation and Research
  • Suzanne L. Bruhn, PhD, Senior VP, Shire Human Genetic Therapies
  • Marc Dunoyer, Global Head, Rare Diseases, GlaxoSmithKline
  • Lynne Fahey McGrath, MPH, PhD, Vice President, North American Head Drug Regulatory Affairs, Novartis Oncology Corporation
  • Dennis Jackman, Senior VP, Public Affairs, CSL Behring
  • Margaret Anderson, Executive Director, FasterCures
  • Jonathan S. Leff, AB, MBA, Managing Director, Warburg Pincus
  • Jeff Allen, PhD, Executive Director, Friends of Cancer Research

While the conference is co-hosted by NORD and DIA, collaborators also include Duke University School of Medicine, the European Rare Diseases Organization (EURORDIS), FDA and NIH.  Topics will include:

  • How federal policies affect patients with rare diseases
  • NIH grant and FDA approval requirements
  • How health care reform will impact rare disease patients
  • Venture philanthropy
  • Clinical trial designs and case examples
  • The economics of investing in orphan products

Information about the conference is available on the NORD website (www.rarediseases.org) and on a special site for online registration hosted by DIA: (http://www.diahome.org/DIAHOME/FlagshipMeetings/Home.aspx?meetingid=26189.

The conference will take place at the Omni Shoreham Hotel in Washington, D.C.   For additional information, contact NORD or DIA.


'/>"/>
SOURCE National Organization for Rare Disorder (NORD)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
4. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
5. ViroPharma to Present at Three Upcoming Healthcare Conferences
6. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Alfacell Corporation to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Research and Markets has announced the addition of the ... ... energy-based aesthetic devices market to grow at a CAGR of 8.12% ... Aesthetic Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:3/29/2017)... , March 29, 2017  BioSpecifics Technologies ... and continues to develop collagenase based-therapies with a ... (CCH) marketed as XIAFLEX ®  in the U.S. ... will present a corporate overview at the upcoming ... Wednesday, April 5, 2017 at 8:00 a.m. ET ...
(Date:3/29/2017)... , Mar. 29, 2017 Research ... Navigation Systems Market 2014 - 2025" report to their ... ... reach USD 303.7 million by 2025. Increasing geriatric population prone ... demand for orthopedic navigation systems over the forecast period. Osteoarthritis ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... ARI Network Services, Inc. (NASDAQ: ARIS) ... eligible dealer websites for its network of more than 650 U.S.-based dealers. Rhino, a ... equipment including rotary and flail mowers and cutters, rear blades, post hole diggers, pasture ...
(Date:3/29/2017)... FL (PRWEB) , ... March 30, 2017 , ... Grass pollen is the main cause ... allergic to the stuff. The season for grass pollen runs from May to July each ... a hay fever victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an ...
(Date:3/29/2017)... ... ... Brand EXOUS Bodygear announced today a special sale price for the EX-701 Knee ... the price will be only $19.97. The EXOUS Bodygear 65cm exercise ball ... $19.97). , The special promotional prices are to help individuals get their products at ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based on research from ... employers face in trying to balance both short-term and long-term benefits demands. ... to the growing complexity, companies are finding that the short-term strategies used to ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... and other outpatient facilities, and who are the most active developers? , ... Revista and Healthcare Real Estate Insights (HREI) found that outpatient medical real estate ...
Breaking Medicine News(10 mins):